Edition:
United States

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

56.41USD
17 Aug 2018
Change (% chg)

$0.59 (+1.06%)
Prev Close
$55.82
Open
$55.77
Day's High
$56.47
Day's Low
$55.30
Volume
40,315
Avg. Vol
29,700
52-wk High
$74.63
52-wk Low
$44.60

Chart for

About

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.... (more)

Overall

Beta: 2.85
Market Cap(Mil.): $667.26
Shares Outstanding(Mil.): 11.83
Dividend: --
Yield (%): --

Financials

  ANIP.OQ Industry Sector
P/E (TTM): 48.82 99.36 30.45
EPS (TTM): 1.16 -- --
ROI: 3.78 2.89 12.63
ROE: 7.46 1.65 14.82

BRIEF-ANI Pharmaceuticals Reports Q1 GAAP Earnings Per Share $0.19

* ANI PHARMACEUTICALS REPORTS FIRST QUARTER 2018 RESULTS AND REAFFIRMS GUIDANCE

May 08 2018

BRIEF-Ani Pharmaceuticals To Acquire Generic Products And Assets From Amneal/Impax

* ANI PHARMACEUTICALS SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE GENERIC PRODUCTS AND ASSETS FROM AMNEAL/IMPAX

Apr 27 2018

BRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution

* ANI PHARMACEUTICALS ANNOUNCES APPROVAL OF MORPHINE SULFATE ORAL SOLUTION

Apr 18 2018

BRIEF-ANI Acquires 23 ANDAs From IDT Australia

April 4 ANI Pharmaceuticals Inc - Deal For $2.6 Mln And A Limited Single :

Apr 04 2018

BRIEF-IDT Australia To Divest Selection Of Generic Product Portfolio To Ani Pharmaceuticals

* TO DIVEST A SELECTION OF ITS GENERIC PRODUCT PORTFOLIO TO ANI PHARMACEUTICALS INC

Apr 03 2018

BRIEF-ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.08

* ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR RESULTS, REPORTS FOURTH QUARTER 2017 RESULTS, AND PROVIDES 2018 GUIDANCE

Feb 27 2018

Earnings vs. Estimates